Bacterial infections are one of the biggest threats to public health, because of increasing and widespread multidrug resistance (MDR). Therefore, novel and effective strategies to develop antibacterial agents are continuously searched.
In this context, PHOBAT aims at developing an effective platform of novel antibacterial agents based on small luminescent organic (triimidazo-triazine and naphthoquinolizinium derivatives) and phosphorescent cyclometalated Pt(II) complexes along with modified peptide nucleic acids PNAs. These compounds will be tested as antimicrobial agents and as PNA carriers leading to potential dual-action systems in which the antisense properties of PNAs are combined with the therapeutic properties of the carrier thus providing, in principle, a synergic effect.
[e-mail]